Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Mometasone + Azelastine FDC vs Monotherapies in SAR
NCT05887843Phase 1Terminated
- Sponsor
- Sandoz
- Start
- Jun 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mometasone furoate + azelastine in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Sandoz. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration, Area Under the Curve from time 0 to infinity and 4 more. Started Jun 2023; status: terminated.
02
Drugs
mometasone furoate + azelastine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT05887843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05887843.